NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Topline Results from DehydraTECH™ Absorption Study
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced positive topline results following the completion of its first ingestible nicotine in vivo absorption study. The company is pursuing the use of its patented DehydraTECH™ technology as a new nicotine delivery method. The delivery method, in the form of an edible dose absorbed through the gastrointestinal tract, could potentially serve as a nicotine replacement therapy or as an alternative product format for regular tobacco users. Among other highlights, DehydraTECH™ demonstrated major nicotine absorption performance improvements including 1,160% faster delivery of equivalent peak quantities of nicotine to…